While other research groups have demonstrated the utility of cytokine-expressing adenovirus vectors to enhance CAR-T cell therapy, the Suzuki group further modified the CAd-VECPDL1 vector by incorporating IL-12 (CAdVECIL12_PDL1) and tested it in a head and neck squamous cell carcinoma (HNSCC) model, as these tumors are often more resistant to CAR-T therapy [95,96]. The gene discussed is CAD; the disease is head and neck squamous cell carcinoma.